Beta Bionics faces a class action lawsuit for allegedly making false statements about the safety and regulatory status of its iLet Bionic Pancreas insulin pump. The lawsuit claims the company misled investors by downplaying FDA concerns after a facility inspection revealed serious issues with device quality and unreported injuries. Investors who bought shares between July 30, 2025, and February 24, 2026, are encouraged to join the case before the November 3, 2026 deadline to seek recovery for losses.
Pump.fun, a Solana-based memecoin launchpad, has reclaimed the top spot in 24-hour protocol revenue with about $1.23 million in fees, overtaking Pons, a newer competitor that had briefly led earlier in 2026. Pons gained rapid traction by leveraging R...
Boyaa Interactive purchased about 205 Bitcoin for $14.3 million between June and September 2026, increasing its total Bitcoin holdings to approximately 4,316 BTC at an average cost of $68,280 per Bitcoin. The company funded these purchases with cash ...
USDT's control depends on the owner role of its smart contract, notably on Tron where a 2-of-3 multisig wallet controls over half of all USDT tokens. This owner role can blacklist addresses, create or destroy tokens, and pause transfers, but cannot a...
McKesson, a leading pharmaceutical distributor in the US oligopoly, generates over $5 billion in free cash flow and is expanding through its oncology segment, which saw a 31% revenue increase year-over-year. The company is strategically acquiring bus...
BDACS has integrated LayerZero's Omnichain Fungible Token (OFT) standard to enable seamless cross-chain transfers of its KRW1 stablecoin, backed 1:1 by Korean won held at Woori Bank. This upgrade unifies KRW1's supply across multiple blockchains, inc...
